Discriminant analysis as a tool to identify compounds with potential as transdermal enhancers

Structure-activity relationships were sought for 73 enhancers of hydrocortisone permeation from propylene glycol across hairless mouse skin. Enhancers had chain lengths (CC) from 0 to 16 carbon atoms, 1 to 8 H-bonding atoms (HB), molecular weight 60 to 450, log P (calculated) −1.7 to 9.7 and log S (calculated) −7.8 to 0.7. These predictive properties were chosen because of their ready availability. Enhancement ratio (ER) was defined as hydrocortisone transferred after 24 h relative to control. Values for the ER ranged from 0.2 to 25.3. Multiple regression analysis failed to predict activity; ER values for the ‘good’ enhancers (ER>10) were underestimated. Simple guidelines suggested that high ER was associated with CC>12 and HB 2–5. This was refined by multivariate analysis to identify significant predictors. Discriminant analysis using CC, HB, and molecular weight correctly assigned 11 of the 12 ‘good’ enhancers (92%). The incorrectly assigned compound was a known, idiosyncratic Br compound. Seventeen of the 61 ‘poor’ enhancers (28%) were incorrectly assigned but four could be considered marginal (ER>8). The success of this simple approach in identifying potent enhancers suggested its potential in predicting novel enhancer activity.

Mechanistic studies on percutaneous penetration enhancement by N-(4-halobenzoyl)-S,S-dimethyliminosulfuranes

Halogen-substituted iminosulfuranes are transdermal penetration enhancers (TPEs) in permeation studies using hairless mouse or human cadaver skin. The interaction of N--(4--R-benzoyl)-S,S-dimethyliminosulfuranes 1--4, where R=H, Cl, Br, and I, with l-alpha-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) has been studied using differential scanning calorimetry, isothermal titration calorimetry, nuclear Overhauser effect spectroscopy (NOESY), and NMR spectroscopy, and by calculation of the iminosulfurane polarizabilities in order to elucidate the molecular basis of the TPE activity. The active compounds reduce the melting temperature of the gel-to-liquid-crystal phase transition and induce multiple components in the transition excess heat capacity profile. The partitioning of the bromo derivative 3, the most active compound, into DMPC is unique in that 3 may be trapped in the bilayer, affording an enhanced residence time and a reason for its high TPE activity. The entropy decrease associated with the transfer of 3 to the bilayer is much lower than that for the other compounds, indicating that 3 occupies or induces sites that afford it considerable local motional freedom. Correlations between the iminosulfurane TPE activities, the partition coefficients, and NOESY crosspeak volume were observed. Molecular polarizabilities are not consistent with a TPE mode of action involving interaction of these agents with protein side chains.

Evaluation of derivatives of 3-(2-oxo-1-pyrrolidine)hexahydro-1H-azepine-2-one as dermal penetration enhancers: side chain length variation and molecular modeling

The present study examined the enhancement effect of two series of compounds derived from 3-(2-oxo-1-pyrrolidine)hexahydro-1H-azepine-2-one. One series possessed alkyl side chains (series I) and the other alkyl ester side chains (series II). An in vitro diffusion study was performed to investigate the effect of variation in alkyl/alkyl ester side chain length of two series of compounds on the permeation of hydrocortisone (HC) across hairless mouse skin. The permeability coefficient (P), 24 h receptor concentration (Q(24)) and skin content (SC), as well as the enhancement ratios (ER) for each parameter were recorded. A parabolic relationship was observed between the ER(P), and the alkyl side chain length of the enhancers. The relationship between the length of ester side chains and ER(P) appeared to be relatively linear with R(2) of 0.9676. The relationship between the calculated lipophilicity (CL) and enhancement activity of the enhancers showed that for CL 5-9, series I showed higher P values compared with Azone, but this was not observed with series II. For CL values 4.57-7.75, a significant correlation existed between P of HC and CL of series II compounds (R(2)=0.9967). 1-Tetradecyl-3-(2-oxo-1-pyrrolidine)-epsilon-caprolactam showed the highest P and Q(24), with 40.5- and 18.6-fold increases over the control. In conclusion, the alkyl side chain series of compounds showed more enhancing activity than the alkyl ester side chain series.

The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities

Four model drugs were selected based on their lipophilicity denoted as log P (nicardipine hydrochloride log P -0.99 +/- 0.1, hydrocortisone log P 1.43 +/- 0.47, carbamazepine log P 2.67 +/- 0.38, and tamoxifen log P 7.87 +/- 0.75). The enhancing activities of four terpene enhancers (fenchone log P 2.13 +/- 0.30, thymol log P 3.28 +/- 0.20, D-limonene log P 4.58 +/- 0.23, and nerolidol log P 5.36 +/- 0.38) were tested in vitro across full thickness hairless mouse skin with each of the evaluated drugs formulated in hydroxypropyl cellulose gel formulations. The relationships between lipophilicity (log P) of the terpene enhancers and model drugs and efficacy (represented by the enhancement ratio of flux ER(flux)) of the drugs when coadministered with the enhancers were examined using linear regression. Terpene enhancers had significant effect on the percutaneous permeation of the model drugs. Nerolidol (highest lipophilicity) provided the highest increase in the flux of the evaluated model drugs. The flux of nicardipine hydrochloride increased by approximately 135-fold, hydrocortisone by 33-fold, carbamazepine 8-fold, and tamoxifen 2-fold. The lowest increase in the flux was observed with fenchone. Linear relationships were generated between the ER(flux) of nicardipine hydrochloride, hydrocortisone, carbamazepine, and tamoxifen and the log P of the terpene enhancers [r = 0.951, (P = 0.049), r = 0.977, (P = 0.023), r = 0.942, (P = 0.057), and r = 0.874, (P = 0.126), respectively]. Furthermore, the four terpene enhancers produced linear relationships, indicating that they were more effective at enhancing the penetration of hydrophilic drugs rather than lipophilic drugs r=-0.824 (P=0.176) for fenchone, r = -0.891 (P = 0.109) for thymol, r = -0.846 (P = 0.154) for limonene, and r = -0.769 (P = 0.232) for nerolidol.

Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir

The purpose of this study was to characterize the relationship between plasma protein binding and the pharmacokinetic disposition of saquinavir during a normal and elevated alpha-1-acid glycoprotein condition. The extent of plasma binding of [14C]saquinavir to human plasma, human albumin, and human alpha-1-acid glycoprotein was also assessed. Transgenic mice, which overexpress plasma alpha-1-acid glycoprotein, and control mice were given a single intravenous injection of saquinavir (10 mg/kg) and plasma samples were harvested as a function of time. The extent of [14C]saquinavir (0.5-30 microg/ml) plasma protein binding in each group of mice was determined by ultrafiltration. Plasma saquinavir concentrations from in vivo administration were determined by high performance liquid chromatography with tandem mass spectrometry. Saquinavir binding in human plasma and control mouse plasma was similar (approximately 3% unbound). In contrast, the extent of binding was significantly increased in transgenic mice (1.5% unbound). Furthermore, saquinavir was more extensively bound to alpha-1-acid glycoprotein than to albumin (2.1 versus 11.5% unbound). The systemic clearance and volume of distribution of saquinavir were significantly reduced in transgenic mice compared with control mice. The results of this study show that alpha-1-acid glycoprotein is the predominant plasma protein to which saquinavir binds. In addition, elevations in plasma alpha-1-acid glycoprotein considerably alter the pharmacokinetic disposition of saquinavir. This is consistent with the observations that systemic exposure to saquinavir in human immunodeficiency virus patients is greater than that in healthy volunteers and that alpha-1-acid glycoprotein levels increase with the degree of HIV infection.

Effect of formulation variables on the percutaneous permeation of ketoprofen from gel formulations

The objectives of our study were to evaluate the effect of four terpene enhancers, enhancer lipophilicity, and ethanol concentration using hydroxypropyl cellulose (HPC) and two Pluronic F-127 (PF-127) gel formulations on the percutaneous permeation of ketoprofen. All experiments were conducted using hairless mouse skin in vitro. Data recorded over 24 hr was compared with that for control gels (containing no terpene) using Franz diffusion cells. In the three gel formulations, the highest increase in the ketoprofen permeation was observed using limonene followed by nerolidol, fenchone, and thymol. Relationships were established between terpene lipophilicity, enhancement ratios for ketoprofen flux (ERflux), and the cumulative amount of ketoprofen after 24 hr (Q24) from the three gel formulations. However, no correlation was established between terpene lipophilicity and ketoprofen skin content values at 24 hr. Ethanol had a synergistic effect on the enhancing activity of the terpenes. Increasing the concentration of ethanol from 10% to 50% was associated with an increase in the permeation of ketoprofen. For example, use of PF-127 gel control (no terpene was included) containing 10% ethanol resulted in a ketoprofen flux of 19 +/- 2 microg/cm2 h and 481 +/- 131 microg/cm2 for Q24. Furthermore, for PF-127 containing 33% ethanol the flux was 34 +/- 3 microg/cm2 h and Q24 was 1,420 +/- 111 microg/cm2. However, HPC gel control that contained 50% ethanol resulted in a ketoprofen flux of 67 +/- 6 microg/cm2 h and 2,839 +/- 222 microg/cm2 for Q24.

The effect of terpene enhancer lipophilicity on the percutaneous permeation of hydrocortisone formulated in HPMC gel systems

The percutaneous permeation of hydrocortisone (HC) was investigated in hairless mouse skin after application of an alcoholic hydrogel using a diffusion cell technique. The formulations contained one of 12 terpenes, the selection of which was based on an increase in their lipophilicity (log P 1.06-5.36). Flux, cumulative receptor concentrations, skin content, and lag time of HC were measured over 24 h and compared with control gels (containing no terpene). Furthermore, HC skin content and the solubility of HC in the alcoholic hydrogel solvent mixture in the presence of terpene were determined, and correlated to the enhancing activity of terpenes. The in vitro permeation experiments with hairless mouse skin revealed that the terpene enhancers varied in their ability to enhance the flux of HC. Nerolidol which possessed the highest lipophilicity (log P = 5.36+/-0.38) provided the greatest enhancement for HC flux (35.3-fold over control). Fenchone (log P = 2.13+/-0.30) exhibited the lowest enhancement of HC flux (10.1-fold over control). In addition, a linear relationship was established between the log P of terpenes and the cumulative amount of HC in the receptor after 24 h (Q(24)). Nerolidol, provided the highest Q(24) (1733+/-93 microg/cm(2)), whereas verbenone produced the lowest Q(24) (653+/-105 microg/cm(2)). Thymol provided the lowest HC skin content (1151+/-293 microg/g), while cineole produced the highest HC skin content (18999+/-5666 microg/g). No correlation was established between the log P of enhancers and HC skin content. A correlation however, existed between the log P of terpenes and the lag time. As log P increased, a linear decrease in lag time was observed. Cymene yielded the shortest HC lag time, while fenchone produced the longest lag time. Also, the increase in the log P of terpenes resulted in a proportional increase in HC solubility in the formulation solvent mixture.

Percutaneous penetration enhancement activity of aromatic S, S-dimethyliminosulfuranes

The activity of three series of iminosulfuranes (classes I-III) as potential transdermal penetration enhancers was investigated. These dimethyl sulfoxide (DMSO) related compounds were synthesized from activated DMSO by trifluoroacetic anhydride. Structure confirmation was accomplished by 1H NMR, and 13C NMR spectroscopy and elemental analysis prior to in vitro testing. Hydrocortisone (HC) was used as a model drug, and the effect of the iminosulfuranes on the penetration of HC through hairless mouse skin was evaluated. All enhancers tested were applied to the skin as saturated suspensions in propylene glycol to ensure their maximum thermodynamic activity. Three compounds, S,S-dimethyl-N-(4-bromobenzoyl)iminosulfurane (9), S,S-dimethyl-N-(5-nitro-2-pyridyl)iminosulfurane (13), and S, S-dimethyl-N-(4-phenylazaphenyl)iminosulfurane (16) showed statistically significant activity quantitated by amounts of model drug permeated through the skin in 24 h (Q(24)), and flux values, compared to control (propylene glycol without enhancer). Highest Q(24) and flux values were obtained for 9: 996.2+/-192.5 microg/cm(2) and 42.9+/-7.5 microg/cm(2) per h, respectively. All arylsulfonyl substituted compounds showed lower or similar enhancement activity when compared to control. S, S-dimethyl-N-(benzenesulfonyl)iminosulfurane (1), S, S-dimethyl-N-(2-methoxycarbonylbenzenesulfonyl)iminosulfurane++ + ( 7) and S,S-dimethyl-N-(4-chlorobenzenesulfonyl)iminosulfurane (8) decreased the permeation of HC significantly (P<0.05). It is possible that these agents work as retardants under these experimental conditions. None of the enhancers tested showed significant skin model drug retention, suggesting that these compounds could be useful for increasing systemic rather than local drug delivery.

Influence of drug lipophilicity on terpenes as transdermal penetration enhancers

Percutaneous absorption-enhancing effects on the skin of hairless mice of 11 monoterpenes [1, (+)-limonene; 2, (-)-menthone; 3, (+)-terpinen-4-ol; 4, alpha-terpineol; 5, 1,8-cineole; 6, (+)-carvone; 7, (-)-verbenone; 8, (-)-fenchone; 9, p-cymene; 10, (+)-neomenthol; and 11, geraniol] were investigated using three different model drugs (caffeine, hydrocortisone, triamcinolone acetonide [TA]) with varying lipophilicities. Terpenes were applied at 0.4 M in propylene glycol (PG) to mouse skin. The model drugs were applied as suspensions in PG 1 hr following enhancer pretreatment. The combination of terpenes in PG provided significant enhancement of the permeation of caffeine through mouse skin. The most active compounds 10 and 11 increased permeation by between 13-fold and 16-fold. The terpenes also enhanced the delivery of hydrocortisone, but not to as great an extent. The most active compounds 3 and 4 increased permeation between 3.9-fold and 5-fold. The compounds examined did not significantly increase the delivery of TA. The most active compound 4 only increased delivery 2.5-fold, while the next most active compound 6 only increased delivery 1.7-fold. Overall, these results indicate that the combination of terpenes with PG can significantly increase the transdermal penetration of the hydrophilic drug caffeine and the polar steroid hydrocortisone.

N-(4-bromobenzoyl)-S,S-dimethyliminosulfurane, a potent dermal penetration enhancer

N-Aroyl-, N-Arylsulfonyl-, and N-Aryl-S,S-dimethyliminosulfuranes have been synthesized and evaluated as potential dermal penetration enhancers. The title compound and Azone exhibit similar activities for permeation of hydrocortisone through hairless mouse skin.

Stability of albuterol in continuous nebulization

Due to the emergent nature of situations requiring continuous nebulization of albuterol a premixed albuterol solution would provide faster access to the therapy when required. The purpose of this study was to evaluate the stability of albuterol solutions at a concentration (200 micrograms/mL) used in continuous nebulization when stored in various containers of polyvinyl chloride bags, polyolefin bags, polypropylene syringes and tubes and borosilicate glass tubes. Solutions were prepared in triplicate in 0.9% sodium chloride stored under refrigerated and room temperatures for seven days. Samples were removed and analyzed using a stability-indicating high-performance liquid chromatrography assay method. Albuterol was found to be stable (greater than 90% of the initial concentration remaining) for at least seven days in all five types of containers under the conditions tested.

Evaluation of transdermal penetration enhancers using a novel skin alternative

A novel alternative to animal skin models was developed in order to aid in the screening of transdermal penetration enhancers. The skin alternative consists of a dermal layer containing human fibroblasts dispersed in a collagen matrix and an epidermal layer of differentiated and stratified human keratinocytes. Skin alternatives were placed in modified Franz diffusion cells (receptor volume 12 mL, donor area 3.14 cm2, n = 5) and enhancer solution (0.4 M in propylene glycol (PG)) was applied. Following 1 h of pretreatment, 10 microL of saturated hydrocortisone (HC) solution in PG was applied, and the cells were occluded with Parafilm. Samples were removed from the receptor compartment over 24 h, replaced with fresh receptor solution, and analyzed for steroid content using HPLC. Skin HC content was also determined. Receptor concentration at 24 h (Q24) for full-thickness skin alternative (control) was 28.6 +/- 13.7 microM and permeability (P) was 8.3 x 10(-4) +/- 5.5 x 10(-4) cm h-1. Azone (1) produced a Q24 of 105.0 +/- 36.1 microM and a P of 11.3 x 10(-4) +/- 1.8 x 10(-4) cm h-1, while the novel penetration enhancer 1-dodecyl-2-pyrrolidinone (2) produced a Q24 of 164.8 +/- 61.2 microM and a P of 33.3 x 10(-4) +/- 6.6 x 10(-4) cm h-1. Compound 3 produced the highest values for all permeability parameters tested with a P of 48.0 +/- 36.8 cm h-1 and a Q24 of 186.1 +/- 45.1 microM. When compared to the control, compound 1 gave an enhancement ratio (ER) of 3.7 for Q24 and 1.4 for P. Compound 2 gives an ER 5.8 for Q24 and 4.0 for P. These enhancement ratios are similar to those found using HC and human skin.

In vitro evaluation of a series of N-dodecanoyl-L-amino acid methyl esters as dermal penetration enhancers

A series of N-dodecanoyl-L-amino acid methyl esters (1-10) and n-pentyl N-acetylprolinate (11) were evaluated for dermal enhancement properties using an in vitro diffusion cell technique. Methods of synthesis of these compounds were described. Enhancers were applied 1 h prior to drug treatment. Hydrocortisone was used as the model drug and was applied to excised hairless mouse skin as a saturated suspension in propylene glycol. Enhancement ratios (ER) were determined for permeability coefficient, 24 h diffusion cell receptor concentration (Q24), and 24 h full-thickness skin steroid content. Controls received no enhancer pretreatment of the skin. N-Dodecanoyl-L-proline (10) showed the highest Q24 value for total steroid (ER 13.7) while N-dodecanoyl-L-phenylalanine (5) showed the highest total steroid skin retention (ER 16.5).

Synthesis and in vitro transdermal penetration enhancing activity of lactam N-acetic acid esters

A homologous series of N-acetic acid esters of 2-pyrrolidinone and 2-piperidinone has been prepared and evaluated for its ability to enhance the skin content and flux of hydrocortisone 21-acetate in hairless mouse skin in vitro. Enhancement ratios (ER) were determined for flux (J), 24-hour diffusion cell receptor cell concentrations (Q24), and 24-h full-thickness mouse skin steroid content (SC) and compared to control values (no enhancer present). In addition, in an attempt to abrogate toxicity, these dermal penetration enhancers were designed to have the potential for biodegradation by dermal esterases. 2-Oxopyrrolidine-alpha acetic acid dodecyl ester (5) showed the highest enhancement ratios for J (ER 67.33) and Q24 (ER 180.66). 2-Oxopiperidine-alpha-acetic acid decyl ester (10) showed a high Q24 (ER 162.07) but a lower J (ER 12.67). 2-Oxopyrrolidine-alpha-acetic acid decyl ester (3) showed the highest enhancement ratio for SC (ER 8.7). The ER Q24 for 3, 5 and 10, as well as other lactam N-acetic acid esters in this work, were significantly higher than the ER found using Azone as enhancer.

Transdermal delivery of drugs with differing lipophilicities using azone analogs as dermal penetration enhancers

Six model drugs were selected for this study based on their degree of lipophilicity as represented by their log P values (range = -0.95 to 3.51). They included 2,4-dihydroxy-5-fluoropyrimidine (5-fluorouracil); 1,3,7-trimethylxanthine (caffeine); [(2-hydroxybenzoyl)amino]-acetic acid (salicyluric acid); 2-hydroxybenzoic acid (salicylic acid); 9 alpha-fluoro-16 alpha-hydroxyprednisolone 16 alpha, 17 alpha-acetonide (triamcinolone acetonide); and alpha-methyl-4-[2-methylpropyl]benzeneacetic acid (ibuprofen). Six dermal penetration enhancers [Azone or 1-dodecylhexahydro-2H-azepin-2-one (1), N-dodecyl-2-pyrrolidinone (2), N-dodecyl-2-piperidinone (3), N-dodecyl-N-(2-methoxyethyl)acetamide (4), N-(2,2-dihydroxyethyl)dodecylamine (5), and 2-(1-nonyl)-1,3-dioxolane (6)] were tested in vitro across full-thickness hairless mouse skin with each of the drugs. The relationship between lipophilicity (log P) and efficacy (represented by the enhancement ratio of flux) of the drugs when coadministered with the enhancers was examined using linear regression. The three cyclic enhancers (1-3) exhibited linear relationships, indicating that they were more effective at enhancing the penetration of hydrophilic drugs R2 = 0.8997 for 1, 0.8801 for 2, and 0.804 for 3) when evaluating all the model drugs except triamcinolone acetonide (TA). The two acyclic enhancers (4 and 5) showed a similar relationship, but their correlation coefficients were lower at 0.6463 for 4 and 0.6213 for 5. Studies with the dioxolane (6) yielded no relationship between the lipophilicity of the drug and the efficacy of the enhancer, with an R2 of 0.002. Overall, 6 was the least effective enhancer studied. The steroid TA was not included in the linear regression analysis. Of the six model drugs studied, TA exhibited the largest increase in transdermal delivery when enhancers 1-6 were used.

A simple and specific high performance liquid chromatography method for the assay of a series of novel dermal penetration enhancers

Synopsis A series of clofibric acid amides has been synthesized and previously reported by the authors as possessing enhancer activity in vitro in athymic nude mouse skin against model drugs, hydrocortisone-21-acetate and beta-methasone-17-valerate. An assay was required for each of these enhancers however, which would be specific for each compound and would also separate model drugs and their metabolite peaks. This study reports reverse phase high performance liquid chromatography assays for clofibric acid amide and seven derivatives (Ia-Ig). All enhancers showed maximum absorption at 232 nm, betamethasone (BM) and its valerate (BMV) at 238 nm, and hydrocortisone (HC) and its acetate (HCA) at 242 nm. Practical units of detection for the amides were 0.46-2.8 mug ml(-1) and peaks were sharp and well-separated from steroid peaks in three vehicles - methanol alone. Franz diffusion cell receptor phase samples (isotonic phosphate buffer), and full-thickness athymic nude mouse skin extracts in methanol. Mobile phases consisted of various proportions of acetonitrile and water, some with 2-propanol. The octyl amide for example, with mobile phase CH(3)CN: H(2)O (85:15) at 1 ml min(-1) had a retention time (t(R)) of 7.9 mins. Under the same conditions, retention times for the steroids were HC, t(R)= 3.3 mins; HCA, t(R)= 4.3 mins; BM, t(R)= 3.4 mins; BMV, t(R)= 4.6 mins. Résumé Les auteurs avaient démontré dans un article précédent le pouvoir accélérateur de pénétration dermique in vitro d'une gamme d'amides d'acide clofibrique sur la peau de souris sans poils, et sans thymus avec des médicaments types tels que l'acetate 21 d'hydrocortisone et le valerate 17 de beta-metasone. Il a cependant été requis, pour chacun de ces accélérateurs, un test spécifique pour chaque composition, permettant de séparer chaque médicament et les pics des métabolites. Cette étude décrit des tests par chromatographie liquide à haute performance en phase inverse pour l'acide chlofibrique et 7 dérivés (Ia-Ig). Tous les accélérateurs ont montré une absorption maximale à 232 nm, la beta-metasone (BM) et son valerate (BMV) à 238 nm, l'hydrocortisone (HC) et son acetate (HCA) à 242 nm. Les unités de détection s'élevaient à 0.46-2.8 mug ml(-1) pour les amides et les pics étaient aigus et distincts des pics stéroïdes et se composaient de 3 véhicules - le méthanol seul, des échantillons du récepteur de cellule de diffusion Franz (tampon du phosphate isotonique) et des extraits de peau de souris sans thymus dans du méthanol. Les phases mobiles étaient constituées de différentes proportions d'acetonitrile et d'eau, certaines avec du propanol-2. L'amide octyl par exemple, avec une phase mobile CH(3)CN: H(2)O (85:15) à 1 ml min(-1) avait un temps de rétention (t(R)) de 7.9 min. Dans des conditions identiques, les temps de rétention pour les stéroïdes étaient les suivants: pour HC, t(R)= 3.3 mins; pour HCA, t(R)= 4.3 mins; pour BM: t(R)= 3.4 mins; pour BMV: t(R)= 4.6 mins.

Facilitated transport of two model steroids by esters and amides of clofibric acid

A series of novel dermal penetration enhancers, esters and amides of clofibric acid, was synthesized. The permeation parameters and skin retention of two steroids (hydrocortisone-21-acetate and betamethasone-17-valerate) in propylene glycol were studied with athymic nude mouse skin by in vitro diffusion cell techniques in the presence of the novel enhancer compounds. Isopropyl myristate, dimethyl lauramide, and 1-dodecylazacycloheptan-2-one (laurocapram, Azone) were used as control enhancers. The most satisfactory enhancement of both the ester and amide series was observed with clofibric acid octyl amide; coadministration increased skin retention of hydrocortisone acetate after 24 h by 3.5-fold and that of betamethasone valerate by 2.9-fold. Diffusion cell receptor concentrations increased 51.6- and 10.3-fold, respectively, during the same time period. However, the enhancer compound in this case was applied to the skin 1 h prior to each of the steroids. The amide analogues were more effective than the equivalent ester compounds of the same carbon chain length. The best enhancer compounds (2c, 3d, 3e, and 3f) were nonirritating to athymic mouse skin in vivo.

A new approach to assessing sweat production

Synopsis Since 1916 when Stillians (1) first reported that excessive axillary sweating could be reduced by the application of 25% aqueous aluminium chloride, sales of antiperspirant products have increased dramatically. In spite of many studies, the mechanism of action of these compounds has not been clearly elucidated (2). In most cases, investigations have been performed on animal foot pads, excised human biopsy specimens and skin samples in vivo (3). A model which eliminated problems encountered in whole body investigations (for example, influence of blood flow) would be preferable. One such method, introduced in part by Sato (3), has been investigated. Preliminary investigations suggest that this method could become useful in the evaluation of the mode of action of antiperspirants. Sweat production was induced using carbachol and methacholine in isolated rat plantar sweat glands. These were maintained in a suitable environment (modified Krebs-Ringer bicarbonate at 38 degrees C containing 30% w/v fresh rat serum). The output of sweat was measured every 5 minutes for 85 minutes and the maximal final volume obtained with any one gland was 23 nanolitres. Sweat production ceased on administration of appropriate concentrations of atropine or the withdrawal of calcium ions from the bathing fluid.

Studies on the mechanism of topical anhidrosis due to polyvalent cations

Synopsis Although eccrine sweat glands are present in the foot pads of many mammals, and are abundant in the general body skin of many of the higher primates, it is only in man that these glands have a thermoregulatory function and are cosmetically significant. The expansion in sales of various antiperspirant products containing complexes of aluminium and zirconium has resulted in many studies, whose aim is to elucidate the mode of action of these substances. Sweat production in the rat foot pad in vivo has been studied, and its modification following topical application of various polyvalent cations. Results of studies of protein precipitation by these cations are also discussed.